Metropolis Healthcare
Metropolis Healthcare Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Metropolis Healthcare
Start SIPMetropolis Healthcare Investment Rating
-
Master Rating:
-
Metropolis Healthcare has an operating revenue of Rs. 1,179.16 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 24% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 34 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Services and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 280 | 257 | 218 |
| Operating Expenses Qtr Cr | 205 | 196 | 172 |
| Operating Profit Qtr Cr | 75 | 61 | 46 |
| Depreciation Qtr Cr | 20 | 20 | 12 |
| Interest Qtr Cr | 7 | 8 | 5 |
| Tax Qtr Cr | 13 | 7 | 10 |
| Net Profit Qtr Cr | 38 | 28 | 63 |
Metropolis Healthcare Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 5
- Bearish Moving Average
- ___
- 11
- 20 Day
- 1340.59
- 50 Day
- 1379.76
- 100 Day
- 1447.25
- 200 Day
- 1623.6
- 20 Day
- 1349.16
- 50 Day
- 1370.22
- 100 Day
- 1456.69
- 200 Day
- 1561.08
Metropolis Healthcare Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1332.24 |
| Second Resistance | 1347.12 |
| Third Resistance | 1363.44 |
| RSI | 49.14 |
| MFI | 52.25 |
| MACD Single Line | -14.18 |
| MACD | -15.01 |
| Support | |
|---|---|
| First Resistance | 1301.04 |
| Second Resistance | 1284.72 |
| Third Resistance | 1269.84 |
Metropolis Healthcare Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 129,509 | 6,410,696 | 49.5 |
| Week | 135,268 | 5,647,439 | 41.75 |
| 1 Month | 150,293 | 5,162,561 | 34.35 |
| 6 Month | 307,583 | 9,944,164 | 32.33 |
Metropolis Healthcare Result Highlights
Metropolis Healthcare Synopsis
NSE-Medical-Services
Metropolis Healthcar is involved in the business activities of Activities of independent diagnostic/pathological laboratories. Company’s Total Operating Revenue is Rs. 1117.13 Cr. and Equity Capital is Rs. 10.23 Cr. for the Year ended 31/03/2022. Metropolis Healthcare Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L73100MH2000PLC192798 and registration number is 192798.| Market Cap | 6,888 |
| Sales | 967 |
| Shares in Float | 2.56 |
| No of funds | 184 |
| Yield | 0.59 |
| Book Value | 8.35 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 19 |
| Alpha | -0.23 |
| Beta | 0.86 |
Metropolis Healthcare
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 49.76% | 49.76% | 49.79% | |
| Mutual Funds | 11.79% | 10.93% | 12.76% | |
| Insurance Companies | 0.94% | 0.95% | 1.09% | |
| Foreign Portfolio Investors | 23.86% | 25.57% | 23.2% | |
| Individual Investors | 9.74% | 9.45% | 9.26% | |
| Others | 3.91% | 3.34% | 3.9% |
Metropolis Healthcare Management
| Name | Designation |
|---|---|
| Dr. Sushil Kanubhai Shah | Chairman & Executive Director |
| Mrs. Ameera Sushil Shah | Managing Director |
| Mr. Hemant Sachdev | Non Exe.Non Ind.Director |
| Mr. Vivek Gambhir | Ind. Non-Executive Director |
| Mr. Sanjay Bhatnagar | Ind. Non-Executive Director |
| Mr. Milind Shripad Sarwate | Ind. Non-Executive Director |
| Ms. Anita Ramachandran | Ind. Non-Executive Director |
Metropolis Healthcare Forecast
Price Estimates
Metropolis Healthcare Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-11-08 | Quarterly Results | |
| 2022-08-10 | Quarterly Results | |
| 2022-07-18 | Others | Inter alia, to consider and approve the revised Audited Standalone Financial results of the Company for the Quarter and Year ended March 31, 2022. per share(400%)Interim Dividend |
| 2022-05-24 | Audited Results | |
| 2022-02-11 | Quarterly Results & Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-02-22 | INTERIM | Rs.8.00 per share(400%)Interim Dividend |
| 2021-02-19 | INTERIM | Rs.8.00 per share(400%)Interim Dividend |
Metropolis Healthcare FAQs
What is Share Price of Metropolis Healthcare ?
Metropolis Healthcare share price is ₹1337 As on 01 February, 2023 | 05:22
What is the Market Cap of Metropolis Healthcare ?
The Market Cap of Metropolis Healthcare is ₹6851.7 Cr As on 01 February, 2023 | 05:22
What is the P/E ratio of Metropolis Healthcare ?
The P/E ratio of Metropolis Healthcare is 44.3 As on 01 February, 2023 | 05:22
What is the PB ratio of Metropolis Healthcare ?
The PB ratio of Metropolis Healthcare is 7.7 As on 01 February, 2023 | 05:22